Colistin the last resort drug in 21st century antibiotics to combat Multidrug resistance superbugs
-
Published:2023-12-31
Issue:6
Volume:11
Page:919-929
-
ISSN:2320-8694
-
Container-title:Journal of Experimental Biology and Agricultural Sciences
-
language:
-
Short-container-title:J Exp Bio & Ag Sci
Author:
Sahoo SwayamprabhaORCID, Mohanty Jatindra NathORCID, Routray Sweta PadmaORCID, Khandia RekhaORCID, Das JayashankarORCID, Shah SejalORCID, Swarnkar TriptiORCID
Abstract
Polymyxin' E' (Colistin) is considered the last resort therapy against Multidrug resistance (MDR) bacteria, mainly Klebsiella peumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli and play a critical role in causing life-threatening infection, and their prevalence is increasing as a big concern globally. Apart from immunological adaptation, chromosomal mutations and plasmid-mediated genes are mostly associated with this resistance at the molecular level. Therefore, the current review extensively focused on Colistin as a drug in 21st-century antibiotics, the activities spectrum with diverse resistance mechanisms of bacteria against Colistin, and emerging approaches of Colistin from discovery to tackling MDR. In the study, we got to know about the challenges and new developments with old weapons like phage therapy as well as new approaches like Phage display and drug repurposing, in addition to the chromosomal and plasmid-mediated genes that play a role in antimicrobial resistance (AMR). The present study would provide insight into the prognostic aspect of combating MDR.
Publisher
Journal of Experimental Biology and Agricultural Sciences
Subject
General Agricultural and Biological Sciences,General Veterinary,General Biochemistry, Genetics and Molecular Biology
Reference76 articles.
1. Abavisani, M., Goudarzi, M., Ghalavand, Z., Hajikhani, B., Rad, Z. R., Rad, Z. R., & Hashemi, A. (2021). Evaluation of efflux pumps overexpression and β-lactamase genes among Colistin resistant Pseudomonas aeruginosa. Gene Reports, 24. https://doi.org/10.1016/j.genrep.2021.101301 2. AbuOun, M., Stubberfield, E. J., Duggett, N. A., Kirchner, M., Dormer, L., et al. (2018). mcr-1 and mcr-2 (mcr-6.1) variant genes identified in Moraxella species isolated from pigs in Great Britain from 2014 to 2015. Journal of Antimicrobial Chemotherapy, 73(10). https://doi.org/10.1093/jac/dky272 3. Abushaheen, M. A., Muzaheed, Fatani, A. J., Alosaimi, M., Mansy, W., et al. (2020). Antimicrobial resistance, mechanisms and its clinical significance. Disease-a-month, 66(6), 100971. https://doi.org/10.1016/j.disamonth.2020.100971 4. Aghapour, Z., Hasani, A., Aghazadeh, M., Rezaee, M. A., Ganbarov, K., et al. (2019). Genes involved in colistin resistance of gram-negative isolates in the northwest of Iran. Gene Reports, 14. https://doi.org/10.1016/j.genrep.2018.12.001 5. Al-Bayssari, C., Dagher, T. N., El Hamoui, S., Fenianos, F., Makdissy, N., Rolain, J. M., & Nasreddine, N. (2021). Carbapenem and colistin-resistant bacteria in North Lebanon: Coexistence of mcr-1 and NDM-4 genes in Escherichia coli. Journal of Infection in Developing Countries, 15(7). https://doi.org/10.3855/jidc.14176
|
|